suggesting that nonverbal voice cues like breath and rate of speech can be helpful in detecting conditions that impact the brain, muscles, heart, and lungs. So, leveraging vocal biomarker functionality as an add-on to existing products could make its solutions more robust and effective for informing treatment.
Pear also forged alliances with two medical research institutions — Cincinnati Children's Hospital and Sweden-based Karolinska Institute — which should get its tech into the hands of more patients. The former is licensing Pear's digital medicine for migraines, while the latter will make use of its digital treatment for irritable bowel syndrome.
Pear is gaining access to innovative tech and forging deals with a range of partners — and casting a wide net could become crucial to DTx firms' survival and expansion efforts. Pear flaunts products that treat or manage more than a health conditions — some of which have been submitted for FDA authorization or earned the upstart big-name academic and commercialization team-ups, per its website.
And news that it's looking to incorporate more cutting-edge features — like VR and vocal biomarker tech — signal that it's taking aggressive steps to better appeal to consumers and potential healthcare partners. Companies inhabiting the crowded DTx market should explore multiple channels of expansion, considering there have been a flurry of worrying signs indicating once-effective modes of expansion might be becoming less stable: A
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »